ALZA Corp Articles

Impax Labs and Teva settle Concerta litigation with J&J units

17 September 2012

Furiex Pharma gets rights to Priligy, some of which it sells on to Menarini

15 May 2012

Impax Labs sued again by J&J unit Alza over generic Concerta

9 May 2011

Impax Labs sued by Johnson & Johnson unit over Concerta patent

1 December 2010

J&J/Actavis recall US lots of fentanyl patches

25 February 2008

Appeals court rules for Mylan on oxybutynin

18 September 2006

US FDA approves Alza's IONSYS

29 May 2006

ALZA resubmits NDA for Ionsys

5 December 2005

Mylan's pain patch gets FDA clearance

7 February 2005

Tenetative US appro for Mylan's oxybutynin

24 January 2005

Theratechnologies sells share in Macroflux projects to Alza

10 January 2005

Pain compound deal for Enhance and Alza

8 November 2004

Approvable letter for Alza's Ionsys

2 August 2004

Appointments at IntraBiotics

19 April 2004

Court rules in Alza's favor in Mylan fentanyl patent case

5 April 2004

Eli Lilly's Strattera gains 16.3% of new Rxs in the USA

27 October 2003

Biotech deals boost strong pharma M&A activity in 2001, says PwC

11 March 2002

J&J halts Topamax obesity trials

11 February 2002

J&J posts healthy increase in sales and earnings for 2001

28 January 2002

Highlights of pharmaceutical mergers and acquisitions during 2001

14 January 2002

J&J posts healthy increase in sales and earnings for 3rd-qtr 2001

17 October 2001

Shire gets US go-ahead for once-daily ADHD product, with launch "imminent"

16 October 2001

PwC report looks at M&A activity in first half of 2001 for pharma and

4 October 2001

Spain's Zeltia sees shares rise amid rumors of Johnson & Johnson takeover

28 September 2001

Datamonitor expresses views on Celebrex vs Vioxx; Novartis ADHD drug

24 September 2001

Gruenenthal acquires rights to Alkermes' DST

6 August 2001

J&J posts healthy increase in sales and earnings, excluding Alza merger

19 July 2001

Alza investigates new approaches to treat urge incontinence

18 July 2001

Alza shareholders approve J&J merger

22 June 2001

Alza to market Ditropan in Canada

14 June 2001

SkyePharma posts strong set of full-year results; profitable by end of 2001

2 April 2001

J&J confirms $10.5 billion bid for Alza

27 March 2001

Johnson & Johnson rumored to be planning takeover bid for Alza Corp

26 March 2001

Alza to set up manufacturing facility in Ireland

27 February 2001

Alza Corp acquires marketing rights to Flexeril from Merck & Co

6 February 2001

Alza Corp revenues pushing $1 billion

1 February 2001

InterMune buys Alza's Amphotec with upfront payment of $9 mill

11 January 2001

UK launch for Schering-Plough's Caelyx

31 October 2000

Alza wins first approval for Concerta

2 August 2000

Alza enrolling KS patients in IM862 trial

27 July 2000

Alza raising $500 mill

25 July 2000

Sanofi-Synthelabo gains UK approval for Ditropan XL

20 June 2000

Alza and Crescendo get FDA approvable letter for ADHD therapy

25 May 2000

Alza's Concerta as effective as three-times daily methylphenidate

18 May 2000

Alza revenues top $200 million mark

20 April 2000

New board members at Orchid

13 April 2000

Stock Commentary New York

2 March 2000

J&J ends Alza JV for E-TRANS - update

23 February 2000

J&J ends Alza JV for E-TRANS

18 February 2000

Schering-Plough files for EMEA Caelyx OK - updated

3 February 2000

Latest crop of full-year results show strong sales growth for US pharma

3 February 2000

S-P files for European OK for Caelyx

28 January 2000

Stock Commentary New York

20 January 2000

US pharmaceutical majors start reporting period with strong performances

20 January 2000

Management shake-up at Alza Corp

13 January 2000

Busy year for NCEs as major new compound classes launched

6 January 2000

1999 mergers suggest move away from life sciences concept to pharmaceuticals

6 January 2000

Abbott Laboratories and Alza Corp call off $7.3 billion merger

17 December 1999

Abbott fined by FDA over quality control, Alza merger under threat

3 November 1999

Abbott sales hit by Abbokinase withdrawal, TAP Holdings "performing

12 October 1999

Lawsuit filed over Abbott & Alza merger

8 October 1999

Alza Corp sets meeting for Abbott merger vote

19 August 1999

Sanofi-Synthelabo's once-daily Ditropan filed in UK

12 August 1999

Healthy first half for many US pharma companies, though revenues may soon

9 August 1999

Alza Corp to push Ditropan sales

23 July 1999

ALZA and Crescendo file for OROS

22 July 1999

Pharmaceutical sales fall at Abbott Labs, Perclose acquired for $680 million

12 July 1999

Funds flowed back into biotech in 2nd qtr 1999, says new study from Burrill

2 July 1999

Ethyol approved for dry mouth in USA

1 July 1999

Ethyol approved for dry mouth in USA

25 June 1999

Stock Commentary New York

24 June 1999

Abbott Laboratories to acquire Alza Corp in $7.3 billion stock deal

22 June 1999

Alza's Ditropan XL Reduces Urinary Incontinence

17 June 1999

FDA panel backs new indication for US Bioscience's Ethyol

15 June 1999

US advisory committee OKs Alza's Doxil

10 June 1999

Final crop of US results for first quarter show encouraging signs

13 May 1999

Alza files sNDA for Doxil

20 April 1999

Schering-Plough heads S&P 500 health co list

29 March 1999

Latest US results for full year 1998 again show strong sales growth

4 February 1999

Updated story - Companies in US biotechnology industry hoping for better

13 January 1999

Mergers & acquisitions in 1998: a lot of wooing but disappointment at the

7 January 1999

Alza's Ditropan cleared by FDA

21 December 1998

Analysts Taking Stock Of Pharma Firms, Prospects Still Good

26 November 1998

Stock Commentary New York

8 October 1998

Alza Boosts Oncology With $580M Sequus Acquisition

6 October 1998

SB Gets Nicotine Clearance In China

24 September 1998

Battle On As Biotech Looks For New Ways Of Funding

8 September 1998

Alza Boosts Ditropan XL Sales Effort

24 August 1998

Healthy Second-Quarter Growth For US Drug Firms

29 July 1998

Promotion At Alza Corp

18 June 1998

Latest Wave Of US 1st Quarter Results

7 May 1998

Appointment At ALZA

5 February 1998

Appointment at Alza Corp

22 January 1998

Product License News In Brief

20 November 1997

US 3rd Quarter Results Show Strong Growth

22 October 1997

Alza Begins Phase III With Duros

16 October 1997

Promotions At Alza Corp

11 September 1997

Trial Results with Alza's Oxybutynin

18 August 1997

New Company Founded; ImmunoTherapies Corp

18 August 1997

Appointments At Alza

31 July 1997

Showing 1-100 of 131 articles

Go to beginningPreviousNextGo to end